FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
Prostamax is a synthetic tetrapeptide, lysine-glutamic acid-aspartic acid-proline, and a member of the short peptide-bioregulator class first described by the Khavinson research group.
Like the other peptides in that class, it is studied not for receptor binding but for sequence-specific interaction with nucleic acids and gene-expression regulation in defined cell models.
The sections below cover the KEDP sequence itself, the peptide-DNA research the Khavinson class is built around, how Prostamax relates to its sibling bioregulators, and the verification underneath each lot.
Research Snapshot
- Prostamax is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and proline, written Lys-Glu-Asp-Pro or KEDP, with the molecular formula C20H33N5O9, a molecular weight of approximately 487.5 g/mol, and CAS number 473578-47-1.
- It belongs to the family of short peptide bioregulators (typically two to four residues) studied by the Khavinson group, a class examined for sequence-specific interactions with DNA in cell-based research models.
- Its research interest is as a defined four-residue sequence used to study how short peptides interact with nucleic acids and influence gene expression in cultured cells of prostate origin, in defined in vitro systems.
- In the bioregulator research toolkit, Prostamax is studied alongside the other short-peptide bioregulators in the catalog, including Vilon (a dipeptide), Thymogen (a dipeptide), and Epithalon (a tetrapeptide).
- Pure Health Peptides supplies Prostamax as a lyophilized Vial in 20 mg and 40 mg sizes, part of the wider catalog. Every lot is finished and tested in the US, routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
Introduction
The short peptide bioregulators are studied as a family, and each one is associated in the research literature with a particular tissue context. Prostamax is the member studied in cultured cells of prostate origin.
That tissue association is a research-model descriptor, the cell type used in the experiments, and the molecule itself is simply a defined four-residue sequence being examined for the same question that defines the whole class: whether a very short peptide can interact selectively with DNA and shape gene expression.
The discussion holds to cell-model and in vitro findings, reads the prostate label as the experimental tissue context and nothing more, and draws no line to applied use.
The Prostamax Tetrapeptide
Structurally, Prostamax is a four-residue peptide with a clearly defined sequence: lysine, then glutamic acid, then aspartic acid, then proline, written Lys-Glu-Asp-Pro or KEDP in single-letter code. Its molecular formula is C20H33N5O9, its molecular weight is near 487.5 g/mol, and it carries CAS number 473578-47-1.
The chemistry of the sequence is what research on this class attends to. The peptide pairs two acidic residues (glutamic and aspartic acid) with a single basic residue (lysine) and a proline that constrains the backbone, and the proposal in the Khavinson literature is that this specific arrangement of side chains carries sequence information that lets the peptide associate with particular stretches of DNA. Because Prostamax is a defined four-residue sequence, its identity is straightforward to confirm by mass spectrometry against its theoretical mass, which is the basis of lot-level verification.
Peptide-DNA Interaction and Gene-Expression Research
The mechanism that makes the short peptide bioregulators a distinct research class is the proposed interaction with nucleic acids. Rather than binding a cell-surface receptor, peptides of this class have been studied for direct, sequence-selective association with DNA, and for the regulation of gene expression that such association could influence, in cell-based study models (Fedoreyeva et al., 2011).
Work on this family describes the peptides entering cells, reaching the nucleus, and showing preferential interaction with particular oligonucleotide sequences in defined in vitro systems. Prostamax is the member of the class examined in cultured cells of prostate origin, and its research literature reports examination of gene-expression regulation in those in vitro models (Anisimov and Khavinson, 2010). The broader work on the class situates these peptides in gene-regulation and bioregulation research (Khavinson, 2002).
All of this is characterized in the in vitro and preclinical terms the literature uses, as molecular-interaction research rather than any applied use. The tissue label attached to Prostamax describes the experimental cell type, not an intended application.
Prostamax in the Bioregulator Research Toolkit
Prostamax is most useful understood in relation to its neighbors, because the short peptide bioregulators are a coherent family studied comparatively.
Vilon is a dipeptide (Lys-Glu) from the same class, Thymogen is a dipeptide (Glu-Trp) studied in thymic-peptide research, and Epithalon is a tetrapeptide (Ala-Glu-Asp-Gly) studied in pineal and telomere research. Holding these side by side lets researchers compare how sequence, length, and tissue association relate to the proposed peptide-DNA behavior.
Held together, these give a research program several defined entry points into the bioregulator question: tetrapeptides (Prostamax, Epithalon) and dipeptides (Vilon, Thymogen), each tied to a different experimental context. Prostamax is the prostate-origin reference among them, supplied as its own lyophilized vial and a distinct tool rather than a substitute for another.
Verification
Underneath the compound is the verification chain. Pure Health Peptides does not manufacture the material; production is sourced from qualified third-party manufacturers, and the material is finished and tested in the US.
Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner, and each qualified lot’s Certificate of Analysis is published in the COA Library, in the vial section, retrievable by batch ID.
For a lyophilized vialed peptide the appropriate panel extends beyond identity, purity, and quantity to include endotoxin and microbial limits, because contamination can enter downstream of synthesis through handling, lyophilization, vial filling, storage, and transit.
The Testing Process page documents how that verification runs, and the Manufacturing Process page covers where the material comes from.
Where Prostamax Sits in Bioregulator Research
For researchers studying the short peptide bioregulators, Prostamax is a specific and well-defined tool: a four-residue sequence associated with prostate-origin cell models, used to study the class-defining question of sequence-specific interaction with nucleic acids.
Its research value rests on that defined sequence and tissue context, and on the comparison it enables against the other peptides in the same class.
As research on short-peptide bioregulation continues, Prostamax remains a useful reference compound, and it holds a clear place in the bioregulator cluster in the catalog.
Frequently Asked Questions
What is Prostamax?
Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP), from the Khavinson family of short peptide bioregulators. It has the molecular formula C20H33N5O9, a molecular weight of approximately 487.5 g/mol, and CAS number 473578-47-1. It is characterized here as a defined research reference material.
What does the KEDP designation mean?
KEDP is the single-letter amino-acid code for Prostamax’s sequence: lysine (K), glutamic acid (E), aspartic acid (D), and proline (P), joined as Lys-Glu-Asp-Pro. Short peptide bioregulators are commonly referred to by these letter codes in the research literature.
What is Prostamax studied for in research?
In controlled laboratory settings it is studied as a short peptide bioregulator. Research literature reports examination of gene-expression regulation in cultured cells of prostate origin, in in vitro models. These are research findings; all applications are non-clinical.
What are Prostamax’s chemical specifications, and what size does it come in?
Prostamax has the molecular formula C20H33N5O9, a molecular weight of approximately 487.5 g/mol, and CAS number 473578-47-1 (refer to the lot-specific Certificate of Analysis for the exact value). It is supplied as a lyophilized powder in 20 mg and 40 mg sizes.
What carrier format is Prostamax available in, and how is it verified?
A lyophilized vial. Every lot is finished and tested in the US and routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 2011;76(11):1210-1219. https://doi.org/10.1134/S0006297911110022
- Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology, 2010;11(2):139-149. https://doi.org/10.1007/s10522-009-9249-8
- Khavinson VK. Peptides and ageing. Neuroendocrinology Letters, 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html



